Phase II clinical trials in Sudan of a therapeutic vaccine to prevent post kala azar dermal leishmaniasis to be supported by European & Developing Countries Clinical Trials Partnership
EVI 20th Anniversary Symposium in Heidelberg, Germany, 20-21 November 2018
European Vaccine Initiative reports positive clinical trial results for two malaria vaccines and calls for further increase in investments into malaria research and development
TRANSVAC is an infrastructure project that aims to accelerate the development of effective vaccines urgently needed to address European and global health challenges. This short movie explains you what the whole initiative is about.
Findings from a workshop organised within the VAC2VAC project (Vaccine batch to vaccine batch comparison by consistency testing) on the improved design of multi-centre validation studies and the use the data generated for product-specific validation purposes have now been published (Halder et al, 2018). The recommendations also address aspects of validation within the consistency approach context
European Vaccine Initiative (EVI) begins its third decade developing vaccines for diseases against poverty. Fundraising management and reporting are crucial aspects for EVI’s strategic planning and stakeholders’ engagement.
Thanks to SAP, EVI’s financial reporting is now streamlined and more efficient. For more information, please click here
EVI has an exciting new Project Manager position. Deadline for applications: 15th January 2018, 17:00 CET. For more information please click here. We look forward to receiving your application.
I4ID, Lyon (France) on December 11-12, 2017
EDCTP funded MVVC2 study published today in Frontiers in Immunology: showing safety and immunogenicity of malaria vectored vaccines given with routine EPI vaccines in Gambian infants and neonates